{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:19:34Z","timestamp":1787653174288,"version":"build-2736575974"},"reference-count":36,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100015272","name":"Societ\u00e0 Italiana di Farmacologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Compassionate drug use (CDU) is a topic of debate in the scientific community characterized by a lack of information, especially in the onco-hematology area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The Compass-O study aimed to provide updated data on CDU of onco-hematological drugs for the period 2016\u20132021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>\n                      Compass-O is a retrospective observational study with data obtained from 7 Italian Units for cytotoxic drug preparations (\n                      <jats:italic toggle=\"yes\">Unit\u00e0 Farmaci Antiblastici, UFA<\/jats:italic>\n                      ). Drugs and Therapeutic Indications (TI) were described separately and as drug-TI combinations, providing the mean Patients Per Year (mPPY) and the Years of Use (YoU).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 783 requests of CDU were retrieved, referring to 156.3 mPPY (max: 272 in 2021; min: 84 in 2018). The 52.2% of subjects was female, and the 63.2% aged &gt;60 years. A total of 709 (90.5%) CDUs referred to solid tumors and 74 (9.5%) to liquid tumors. CDU referred to 93 drug-TI combinations. The most recurrent drug-TIs were nivolumab-lung carcinoma (mPPY: 36.5; YoU: 2) for solid tumors, and azacytidine-acute myeloid leukemia (6.0; 1) for liquid tumors. The most frequent TIs were lung carcinoma (45.7; 6) and breast cancer (37.0; 4) for solid tumors, and chronic lymphocytic leukemia (5.0; 2) and multiple myeloma (4.7; 6) for liquid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compass-O provided an updated framework of the CDU in onco-hematology, showing its large-scale phenomenon and the relevance of UFA as a data source, underlining the need for a national observatory to monitor CDU.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251327117","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T18:01:56Z","timestamp":1741888916000},"page":"1008-1015","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Facts and figures of the compassionate use of onco-hematological drugs from 2016 to 2021: Results from the multicentric observational study Compass-O"],"prefix":"10.1177","volume":"32","author":[{"given":"Annamaria","family":"Mascolo","sequence":"first","affiliation":[{"name":"Department of Experimental Medicine, Section of Pharmacology \u201cL. Donatelli\u201d, University of Campania \u201cLuigi Vanvitelli\u201d, \rNapoli, Italy"},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Napoli, Italy"},{"name":"Link Campus University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Dell\u2019Anno","sequence":"additional","affiliation":[{"name":"Fondazione ReS (Ricerca e Salute \u2013 Health and Research Foundation), Roma, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Dondi","sequence":"additional","affiliation":[{"name":"Fondazione ReS (Ricerca e Salute \u2013 Health and Research Foundation), Roma, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Section of Pharmacology \u201cL. Donatelli\u201d, University of Campania \u201cLuigi Vanvitelli\u201d, \rNapoli, Italy"},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Section of Pharmacology \u201cL. Donatelli\u201d, University of Campania \u201cLuigi Vanvitelli\u201d, \rNapoli, Italy"},{"name":"Campania Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Napoli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialuisa","family":"Giordano","sequence":"additional","affiliation":[{"name":"P.O. Monaldi, A.O. Ospedali Dei Colli, Napoli, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Cristinziano","sequence":"additional","affiliation":[{"name":"P.O. Monaldi, A.O. Ospedali Dei Colli, Napoli, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-736X","authenticated-orcid":false,"given":"Domenico","family":"Tarantino","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Pani","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Roma, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Masini","sequence":"additional","affiliation":[{"name":"Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d \u2013 IRCCS, Meldola, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Donati","sequence":"additional","affiliation":[{"name":"Istituto Romagnolo per lo Studio dei Tumori \u201cDino Amadori\u201d \u2013 IRCCS, Meldola, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Rossin","sequence":"additional","affiliation":[{"name":"ASST Fatebenefratelli Sacco"},{"name":"ASST Valle Olona, Busto Arsizio, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Lagana","sequence":"additional","affiliation":[{"name":"ASST Valle Olona, Busto Arsizio, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ballerio","sequence":"additional","affiliation":[{"name":"ASST Valle Olona, Busto Arsizio, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Bagaglini","sequence":"additional","affiliation":[{"name":"ASL Latina, Ospedale S.M. Goretti, Latina, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Bonanni","sequence":"additional","affiliation":[{"name":"ASL Latina, Ospedale S.M. Goretti, Latina, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Vergati","sequence":"additional","affiliation":[{"name":"P.O. Belcolle, ASL Viterbo, Viterbo, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Cavaliere","sequence":"additional","affiliation":[{"name":"P.O. Belcolle, ASL Viterbo, Viterbo, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Celenza","sequence":"additional","affiliation":[{"name":"A.O. di Perugia \u2013 Ospedale Santa Maria della Misericordia, Perugia, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"D\u2019Arpino","sequence":"additional","affiliation":[{"name":"A.O. di Perugia \u2013 Ospedale Santa Maria della Misericordia, Perugia, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nello","family":"Martini","sequence":"additional","affiliation":[{"name":"Fondazione ReS (Ricerca e Salute \u2013 Health and Research Foundation), Roma, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-8961","authenticated-orcid":false,"given":"Carlo","family":"Piccinni","sequence":"additional","affiliation":[{"name":"Fondazione ReS (Ricerca e Salute \u2013 Health and Research Foundation), Roma, Italia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/2168479017694848"},{"key":"e_1_3_3_3_2","article-title":"Applying real-world data from expanded-access (\u201ccompassionate use\u201d) patients to drug development","volume":"7","author":"Wasser JS","year":"2023","unstructured":"Wasser JS, Greenblatt DJ. Applying real-world data from expanded-access (\u201ccompassionate use\u201d) patients to drug development. J Clin Transl Sci [Internet] 2023; 7: e181.","journal-title":"J Clin Transl Sci [Internet]"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2016-103917"},{"key":"e_1_3_3_5_2","unstructured":"European Parliament. Regulation - 726\/2004 - EN - EUR-Lex [Internet] https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=CELEX%3A32004R0726 (2004 accessed 3 Apr 2024)."},{"key":"e_1_3_3_6_2","first-page":"43","article-title":"Compassionate drug uses in Italy. Analysis of regional and local diffusion","volume":"59","author":"Pilunni D","year":"2023","unstructured":"Pilunni D, Navarra P. Compassionate drug uses in Italy. Analysis of regional and local diffusion. Ann Ist Super Sanita [Internet] 2023; 59: 43\u201350.","journal-title":"Ann Ist Super Sanita [Internet]"},{"key":"e_1_3_3_7_2","article-title":"The economic impact of compassionate use of medicines","volume":"21","author":"Jommi C","year":"2021","unstructured":"Jommi C, Pantellini F, Stagi L, et al. The economic impact of compassionate use of medicines. BMC Health Serv Res [Internet] 2021; 21: 1303.","journal-title":"BMC Health Serv Res [Internet]"},{"key":"e_1_3_3_8_2","article-title":"PNS410 Data from expanded access programs: treatment first, collection second. An overview of FDA and EMA regulatory approvals","volume":"22","author":"Polak T","year":"2019","unstructured":"Polak T, Uyl-de Groot CA, Van Rosmalen J. PNS410 Data from expanded access programs: treatment first, collection second. An overview of FDA and EMA regulatory approvals. Value Heal [Internet] 2019; 22: S835.","journal-title":"Value Heal [Internet]"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijp.IJP_665_20"},{"key":"e_1_3_3_10_2","article-title":"International country-level trends, factors, and disparities in compassionate use access to unlicensed products for patients with serious medical conditions","volume":"3","author":"Aliu P","year":"2022","unstructured":"Aliu P, Sarp S, Reichenbach R, et al. International country-level trends, factors, and disparities in compassionate use access to unlicensed products for patients with serious medical conditions. JAMA Heal forum [Internet] 2022; 3: e220475.","journal-title":"JAMA Heal forum [Internet]"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2186-y"},{"key":"e_1_3_3_12_2","article-title":"CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program","volume":"10","author":"Guolo F","year":"2020","unstructured":"Guolo F, Fianchi L, Minetto P, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer J [Internet] 2020; 10: 96.","journal-title":"Blood Cancer J [Internet]"},{"key":"e_1_3_3_13_2","first-page":"6365","article-title":"Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli","volume":"25","author":"Pilunni D","year":"2021","unstructured":"Pilunni D, Daloisio V, Campopiano R, et al. Compassionate drug uses and saving for the national health system: the case study of Fondazione Policlinico Gemelli. Eur Rev Med Pharmacol Sci [Internet] 2021; 25: 6365\u20136377.","journal-title":"Eur Rev Med Pharmacol Sci [Internet]"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-024-01381-z"},{"key":"e_1_3_3_15_2","unstructured":"AIFA. Compassionate use programmes | Italian Medicines Agency [Internet] https:\/\/www.aifa.gov.it\/en\/farmaci-a-uso-compassionevole (2025 accessed 20 Feb 2025)."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6360"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01879-4"},{"key":"e_1_3_3_18_2","unstructured":"American Cancer Society. Key statistics for acute myeloid leukemia (AML) | American Cancer Society [Internet] https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/about\/key-statistics.html (2024 accessed 12 Apr 2024)."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26354"},{"key":"e_1_3_3_20_2","first-page":"45","article-title":"Epidemiology of lung cancer","volume":"25","author":"Thandra KC","year":"2021","unstructured":"Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of lung cancer. Contemp Oncol (Poznan, Poland) [Internet] 2021; 25: 45\u201352.","journal-title":"Contemp Oncol (Poznan, Poland) [Internet]"},{"key":"e_1_3_3_21_2","volume-title":"StatPearls [Internet]","author":"Sundararajan S","year":"2024","unstructured":"Sundararajan S, Thida AM, Yadlapati S, et al. Metastatic melanoma [Internet]. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing, 2024."},{"key":"e_1_3_3_22_2","first-page":"1","article-title":"Cancer and aging: two tightly interconnected biological processes","volume":"13","author":"Berben L","year":"2021","unstructured":"Berben L, Floris G, Wildiers H, et al. Cancer and aging: two tightly interconnected biological processes. Cancers (Basel) [Internet] 2021; 13: 1\u201320.","journal-title":"Cancers (Basel) [Internet]"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.7002"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114912"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.09.011"},{"key":"e_1_3_3_26_2","article-title":"Immune checkpoint inhibitors and immune-related adverse drug reactions: Data from Italian pharmacovigilance database","volume":"11","author":"Ruggiero R","year":"2020","unstructured":"Ruggiero R, Fraenza F, Scavone C, et al. Immune checkpoint inhibitors and immune-related adverse drug reactions: Data from Italian pharmacovigilance database. Front Pharmacol [Internet] 2020; 11: 830.","journal-title":"Front Pharmacol [Internet]"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","unstructured":"Grivas P Barata PC Moon HH et al. Avelumab first-line maintenance therapy for locally advanced\/metastatic urothelial carcinoma: Results from the real-world US PATRIOT-II study. American Society of Clinical Oncology 2024; 42: 697\u2013697.","DOI":"10.1200\/JCO.2024.42.4_suppl.697"},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","unstructured":"Antonuzzo L Maruzzo M De GU et al. READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la\/mUC). American Society of Clinical Oncology 2023; 41: 469\u2013469.","DOI":"10.1200\/JCO.2023.41.6_suppl.469"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2257885"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.003"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23654"},{"key":"e_1_3_3_35_2","article-title":"Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Results of the compassionate use or the expanded access program in Spain","volume":"15","author":"de la Rubia J","year":"2023","unstructured":"de la Rubia J, Alonso R, Clavero ME, et al. Belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: Results of the compassionate use or the expanded access program in Spain. Cancers (Basel) [Internet] 2023; 15: 2964.","journal-title":"Cancers (Basel) [Internet]"},{"key":"e_1_3_3_36_2","article-title":"Which is the top player for the cardiovascular safety? Ibrutinib vs. obinutuzumab in CLL","volume":"14","author":"Mascolo A","year":"2023","unstructured":"Mascolo A, Di Napoli R, Balzano N, et al. Which is the top player for the cardiovascular safety? Ibrutinib vs. obinutuzumab in CLL. Front Pharmacol [Internet] 2023; 14: 1229304.","journal-title":"Front Pharmacol [Internet]"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04419-w"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251327117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251327117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251327117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:31:42Z","timestamp":1787650302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251327117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/10781552251327117"],"URL":"https:\/\/doi.org\/10.1177\/10781552251327117","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}